422 filings
8-K
COCP
Cocrystal Pharma, Inc.
31 Oct 24
Regulation FD Disclosure
9:10am
8-K
COCP
Cocrystal Pharma, Inc.
10 Oct 24
Departure of Directors or Certain Officers
5:02pm
8-K
COCP
Cocrystal Pharma, Inc.
20 Aug 24
Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences
8:00am
8-K
COCP
Cocrystal Pharma, Inc.
14 Aug 24
Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:15am
10-Q
2024 Q2
COCP
Cocrystal Pharma, Inc.
Quarterly report
14 Aug 24
8:00am
8-K
9rlll8b361y
18 Jul 24
Regulation FD Disclosure
9:00am
8-K
l2hjcnk9ezuy7qn
28 Jun 24
Amendments to Articles of Incorporation or Bylaws
4:01pm
8-K
jbxxpfb
20 Jun 24
Regulation FD Disclosure
8:30am
8-K
62z cyn1p
13 May 24
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:15am
8-K
khktdkaza6
1 May 24
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
8:00am
8-K
p94mw2os
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
8-K
dgog up1wutl9
19 Mar 24
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
8:30am
8-K
85hahq32z aw8p
1 Mar 24
Termination of a Material Definitive Agreement
4:15pm
8-K
pfw2gz5aj4gf
8 Jan 24
Regulation FD Disclosure
8:00am
8-K
2ihbb8ajkqiz 1i4l
4 Jan 24
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
4:01pm